Business
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned.
Patented medications and their active ingredients would be hit with a 100% tariff, according to a draft of the document obtained by CNBC. But there are pathways for drugmakers to reduce or avoid the levies if they move their manufacturing to the U.S. or are negotiating deals with the administration.
The proposal is not final and it is unclear when the Trump administration may announce it, though some reports indicated it could be as soon as Thursday.
The plan would represent another shift in Trump’s aggressive trade strategy, more than a month after the Supreme Court struck down the global levies he imposed in 2025, which excluded the pharmaceutical industry.
US President Donald Trump (C), alongside Secretary of Health and Human Services Robert F. Kennedy Jr. (R) and National Institute of Health (NIH) Director Jayanta Bhattacharya (L), speaks during a news conference about prescription drug prices, in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC.
Jim Watson | Afp | Getty Images
Since November, more than a dozen major drugmakers, including Eli Lilly, Pfizer and Novo Nordisk, have inked deals with Trump to lower the prices of new and existing medicines. Those agreements are part of the president’s “most favored nation” policy, which ties U.S. drug prices to cheaper ones abroad, and exempted the companies from tariffs for three years.
Drugmaker that have fully executed deals or are currently negotiating with the Health and Human Services department would be exempt from the tariffs.
As part of the draft proposal, the administration would impose a 20% tariff on companies that plan to onshore production, which would increase to 100% four years from now.
Meanwhile, there are separate rates for the EU, Japan, South Korea, Switzerland and the U.K. based on bilateral deals. There will also be zero additional tariffs on generic drugs, according to the draft document.
The White House did not immediately respond to a request for comment on the draft pharmaceutical tariff plan.
The tariffs follow a Commerce Department investigation that determined certain pharmaceutical imports pose a national security risk to the United States.
Prior to the landmark drug pricing deals, Trump repeatedly threatened duties on pharma imports. Those threats – and efforts to get into the president’s good graces – fueled a new wave of U.S. manufacturing investments from the pharmaceutical industry. Those commitments come at a time when domestic drug manufacturing had shrunk significantly.
Bloomberg first reported on the new pharmaceutical tariffs late Wednesday.
Business
Stock market this week: Middle East tensions, oil prices, FII flows & more — what will guide Dalal Street
Dalal Street is heading into the new trading week with global uncertainty firmly in focus, as investors keep a close watch on the evolving situation in the Middle East, fluctuations in crude oil prices and the behaviour of foreign investors. Analysts said that sentiment is likely to remain fragile and heavily influenced by developments in negotiations between the United States and Iran, while movements in the rupee, global equities and the US dollar are also expected to shape market direction in the days ahead.Trading activity during the week is also expected to be shaped by the rupee’s movement against the US dollar, while investors continue to assess the impact of global uncertainty on risk appetite. Markets will remain closed on Thursday for Bakri Id.A key trigger for sentiment emerged over the weekend after US Secretary of State Marco Rubio said negotiations between Washington and Tehran had shown some progress, raising expectations that the ongoing conflict in West Asia could move closer to resolution.Ajit Mishra, SVP, Research at Religare Broking Ltd, said investors would closely track developments tied to crude oil, global currencies and bond markets. “This week is expected to remain highly sensitive to global macroeconomic developments and currency movements. Investors will also monitor crude oil prices, developments in US-Iran negotiations, and the trajectory of the US dollar and bond yields, all of which are expected to influence foreign flows and overall risk appetite,” he said.Apart from geopolitical developments, the Reserve Bank’s decision to transfer a record Rs 2.87 lakh crore dividend to the government for the year ended March 2026 is also expected to remain in focus. The announcement comes at a time when rising import costs and supply chain pressures linked to the West Asia conflict continue to weigh on the economy.According to Mishra, market participants are expected to evaluate how the RBI payout could affect liquidity conditions, fiscal flexibility and government spending in the months ahead.Ponmudi R, CEO of Enrich Money, said market behaviour in the coming sessions is expected to remain sensitive to fresh headlines surrounding diplomatic negotiations and oil prices. “Markets are expected to remain volatile and heavily headline-driven in the coming week, with investor attention firmly focused on developments surrounding the US–Iran situation, broader diplomatic negotiations and movements in crude oil prices,” he said.“While hopes of a diplomatic breakthrough and easing geopolitical tensions have improved sentiment modestly, investors continue to remain cautious as uncertainty surrounding the final outcome of the negotiations remains elevated,” Ponmudi added.He further said investors are expected to watch institutional flows, global equity trends, macroeconomic indicators and the rupee for further market cues. “With global uncertainty still elevated, market participants are likely to remain selective and cautious despite the recent improvement in sentiment,” he said.Vinod Nair, Head of Research at Geojit Investments Limited, said markets would require stronger support factors to build a more constructive setup. According to him, a meaningful decline in crude oil prices, steady foreign institutional investor flows and stable Q1FY27 earnings expectations without major downgrades would be important for sustained momentum.In the previous week, the BSE benchmark index rose 177.36 points, or 0.23%, while the NSE Nifty advanced 75.8 points, or 0.32%.
Business
‘Shameful’ more spent on benefits than jobs for young people, says adviser Alan Milburn
Reforms are needed of the welfare system to tackle the high numbers of young people not in work or education, says Alan Milburn.
Source link
Business
Pets at Home hoping for boost under new boss despite consumer pressure
Pets at Home investors will be hoping the retailer’s new boss can lay out a strategy to return it to profit growth despite a challenging consumer backdrop.
Shares in the company currently sit close to its lowest level for almost seven years following a recent downturn in the group’s retail arm.
The dip in the group’s performance contributed to the departure of previous chief executive Lyssa McGowan late last year.
In March, former Waitrose boss James Bailey took the reins in a bid to drive a turnaround in performance.
Shareholders will be hoping the new boss can show early signs of improvement and a long-term strategy to drive growth in Pets at Home’s update on Wednesday May 27.
The pet products retailer and vet chain is expected to report an underlying pre-tax profit of around £93 million for the year to March, according to analysts.
It would represent a roughly 30% fall from last year, after the company came under pressure from weak demand for discretionary products.
Analysts have said investors will be looking at early trading in the current financial year to see how consumer spending is holding up.
AJ Bell’s investment director Russ Mould said: “Pets at Home could badly do with some renewed pep.
“Under executive chair Ian Burke, who has returned to a non-executive role after leading the business on an interim basis, Pets at Home laid out a plan to fix a retail business which has been badly affected by a reduction in discretionary spend on toys and treats for Britons’ furry and feathered friends.
“The country may have a reputation for loving their animal companions but in an environment where households are having to watch their pennies, these nice-to-have items were off the list.”
The group has also seen sales of pet food and similar products face fierce pricing competition from non-specialist retailers, such as supermarkets.
It has since cut prices among around 1,000 products in order to help drive activity, with cash-strapped shoppers looking for value.
Data from the Office for National Statistics (ONS) showed that UK retail sales volumes dropped to an 11-month low in April, with a 1.3% fall for the month.
Pets at Home is predicted to report revenues of £1.47 billion for the past year, just marginally lower than £1.482 billion reported last year.
-
Entertainment1 week agoWhere Pete Davidson, Elsie Hewitt stand after breakup: Details revealed
-
Politics1 week agoRising diesel costs from Iran war strain US school budgets
-
Tech1 week agoGreg Brockman Officially Takes Control of OpenAI’s Products in Latest Shakeup
-
Tech1 week agoWhy Is Your Grill So Dumb? The Best Grills Set Temp Like an Oven
-
Fashion1 week agoRMG trade bodies seek policy support from Bangladesh PM
-
Tech1 week agoThis Solar-Powered Smart Sprinkler Keeps My Lawn Watered Without Any Power Cables
-
Business1 week agoOil price gains and Westminster worry sink stocks
-
Tech1 week agoTesla Reveals New Details About Robotaxi Crashes—and the Humans Involved
